<DOC>
	<DOCNO>NCT01068600</DOCNO>
	<brief_summary>This 12-week study evaluate efficacy safety indacaterol versus placebo .</brief_summary>
	<brief_title>Comparison Efficacy Indacaterol Versus Placebo Over 12 Weeks</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Diagnosis COPD ( moderatetosevere classify Global Initiative Chronic Obstructive Lung Disease ( GOLD ) Guidelines , 2008 ) : 1 . Smoking history least 10 packyears 2 . Postbronchodilator FEV1 &lt; 80 % â‰¥30 % predict normal value 3 . Postbronchodilator FEV1/FVC ( force vital capacity ) &lt; 70 % Patients COPD exacerbation require systemic corticosteroid and/or antibiotic and/or hospitalization 6 week prior screen Patients respiratory tract infection within 6 week prior screen Patients concomitant pulmonary disease Patients history asthma Patients diabetes Type I uncontrolled diabetes Type II Any patient lung cancer history lung cancer Patients history certain cardiovascular comorbid condition Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>Indacaterol</keyword>
</DOC>